Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, was featured in a trial-in-progress poster at the The ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, FL.
In a poster (Abstract #TPS23) titled "A Phase 1 Study Evaluating COM701 Monotherapy and in Combination with Nivolumab in Patients With Advanced Solid Malignancies," the Company reported the following:
Enrollment in the eighth dose level patient cohort of 20mg/kg at Q4 weekly dosing schedule is ongoing in the monotherapy dose escalation study.
Enrollment in the fourth dose level patient cohort at Q4 weekly dosing schedule in the combination dose escalation study of COM701 with Opdivo® (nivolumab) has been completed with no dose-limiting toxicities reported.
No dose limiting toxicities have been reported in lower dose level patient cohorts in the monotherapy and combination dose escalation arms.
The poster is available on Compugen's website at www.cgen.com.